Immunome, Inc. (NASDAQ:IMNM) Stake Reduced by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC trimmed its stake in Immunome, Inc. (NASDAQ:IMNM) by 5.0% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 39,500 shares of the company’s stock after selling 2,070 shares during the quarter. Wealth Enhancement Advisory Services LLC owned approximately 0.07% of Immunome worth $577,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. Northeast Financial Consultants Inc acquired a new stake in shares of Immunome in the 2nd quarter worth about $883,000. The Manufacturers Life Insurance Company increased its stake in shares of Immunome by 52.2% in the second quarter. The Manufacturers Life Insurance Company now owns 166,928 shares of the company’s stock valued at $2,020,000 after purchasing an additional 57,242 shares during the period. AQR Capital Management LLC raised its holdings in shares of Immunome by 34.6% during the second quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock valued at $194,000 after buying an additional 4,129 shares during the last quarter. AXA S.A. acquired a new position in shares of Immunome during the second quarter worth approximately $2,174,000. Finally, Marshall Wace LLP boosted its position in shares of Immunome by 228.5% during the second quarter. Marshall Wace LLP now owns 1,713,325 shares of the company’s stock worth $20,731,000 after buying an additional 1,191,774 shares during the period. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Price Performance

IMNM opened at $12.54 on Friday. The business has a 50 day moving average price of $13.43 and a two-hundred day moving average price of $13.90. The company has a market capitalization of $753.08 million, a price-to-earnings ratio of -1.63 and a beta of 1.82. Immunome, Inc. has a 1-year low of $6.93 and a 1-year high of $30.96.

Immunome (NASDAQ:IMNM) last announced its earnings results on Monday, August 12th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.11). The firm had revenue of $2.36 million for the quarter, compared to the consensus estimate of $2.62 million. Immunome had a negative net margin of 2,435.02% and a negative return on equity of 38.19%. Equities analysts expect that Immunome, Inc. will post -1.92 EPS for the current fiscal year.

Insider Buying and Selling

In other Immunome news, CFO Max Rosett sold 14,380 shares of Immunome stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $16.01, for a total value of $230,223.80. Following the transaction, the chief financial officer now owns 47,476 shares in the company, valued at approximately $760,090.76. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Immunome news, CFO Max Rosett sold 14,380 shares of the business’s stock in a transaction dated Thursday, September 19th. The stock was sold at an average price of $16.01, for a total transaction of $230,223.80. Following the sale, the chief financial officer now owns 47,476 shares in the company, valued at approximately $760,090.76. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jack Higgins sold 3,524 shares of Immunome stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $13.93, for a total transaction of $49,089.32. Following the completion of the transaction, the insider now directly owns 16,000 shares in the company, valued at approximately $222,880. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 8.60% of the company’s stock.

Wall Street Analysts Forecast Growth

IMNM has been the topic of several analyst reports. Piper Sandler lowered their target price on Immunome from $27.00 to $23.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 13th. Wedbush reissued an “outperform” rating and set a $33.00 price target on shares of Immunome in a report on Friday, October 25th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $29.00.

Immunome Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.